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Influence of abnormal potassium levels on mortality among hospitalized
heart failure patients in the US: data from National Inpatient Sample
Sijan Basnet a, Rashmi Dhitala, Biswaraj Tharu b, Sushil Ghimirea, Dilli Ram Poudel a
and Anthony Donato a
aDepartment of Internal Medicine, Reading Hospital and Medical Center, West Reading, PA, USA; bDepartment of Internal Medicine,
Trumbull Regional Medical Center, Warren, OH, USA
ABSTRACT
Background: Abnormalities in serum potassium levels have been associated with variable
mortality risk among hospitalized patients with heart failure (HF). We aim to use a large
database study to further characterize risk of mortality, demographic factors, and associated
comorbidities among heart failure inpatients.
Methods: Our sample population was from the US National Inpatient Sample database from
the year 2009–2011. The inclusion criteria used to identify patients was those with a diagnosis
of heart failure as per ICD-9 classification. Other demographic factors considered in data
collection included income, and cardiac risk factors. Taking these factors into consideration,
a univariate association of potassium level and mortality was performed, as well as multi-
variable logistic regression controlling for demographic factors and associated conditions.
Results: Of the 2,660,609 patients who were discharged with a diagnosis of heart failure
during this time period, patients with hypokalemia during hospitalization had increased
mortality risk (OR: 1.96, 95% CI: 1.91–2.01) when compared with those with hyperkalemia
who had decreased inpatient mortality risk OR: 0.94,95% CI: 0.91–0.96) versus those not
coded for potassium abnormalities. This finding was significant even regardless of the
etiology of the hypokalemia while the hyperkalemic patients were noted to have no differ-
ence or a decreased risk in all subtypes and groups.
Conclusion: Unlike heart failure patients with hyperkalemia, those with hypokalemia are at an
increased inpatient mortality risk. Whether our mortality findings translate to longer-term
outpatient settings where significantly less monitoring is possible is a matter for further study.
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According to the American Heart Association,
approximately 6.5 million adults in the USA (US) are
living with heart failure (HF) [1]. In 2014, 68,626 had
heart failure listed as the underlying cause of death [1].
Among heart failure patients, studies have shown
that hypokalemia, in comparison to normokalemia,
has been associated with increased risk of mortality,
with hazard ratios ranging from 1.2 to 2.3 [2–5].
Decrease in potassium levels by >15% or >0.7 mmol/l,
even within normal range among patients admitted
with acute decompensated heart failure was associated
with increased 180-day all-cause mortality [6].
Hypokalemia in patients with heart failure has been
postulated to be caused by the use of non-potassium
sparing diuretics and activation of neurohormones
[3,5,7]. Low serum potassium is known to increase the
transmembrane resting potential of myocardial cells,
resulting in hyperpolarization and increased excitabil-
ity. Increased excitability leads to a higher risk of ven-
tricular arrhythmia [4,5,8], which is the most common
cause of sudden cardiac death in heart failure patients
[9]. This may be especially relevant in heart failure
patients with structural heart disease such asmyocardial
infarction and valvular heart disease, where effects of
potassium are currently unknown [2,4,5,10]. On the
other hand, hyperkalemia has been associated with
both increased and decreased mortality risk in various
outpatient studies [5,11–14]). Studies have reported no
association between lower ranges of hyperkalemia (K
5.0–6.0 mEq/l) and death [5], an association between
hyperkalemia and fewer deaths [11] and association
between hyperkalemia and higher rates of death and
hospitalization [12–14]. Patients with heart failure, par-
ticularly those on angiotensin-converting enzyme
(ACE) inhibitors, angiotensin-receptor blockers
(ARBs) and aldosterone receptor antagonists are sus-
ceptible to develop hyperkalemia [15]. Therefore it is
critical to understand whether these evidence-based
medications can have their doses safely increased with-
out concerns for provoking additional mortality risk.
In order to better characterize some of the discre-
pancies in observed effects and establish relationship
between in-hospital mortality among heart failure
CONTACT Sijan Basnet sijanbasnet@gmail.com Department of Medicine, Reading Hospital and Medical Center, West Reading, PA 19611, USA
Supplemental data for this article can be accessed here.
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES
2019, VOL. 9, NO. 2, 103–107
https://doi.org/10.1080/20009666.2019.1593778
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
patients and serum potassium levels, we studied a large
US inpatient database (National Inpatient Sample) to
ascertain relationships between diagnosed potassium
disorders and inpatient mortality.
2. Methods
2.1. Study population
We utilized the National Inpatient Sample (NIS)
database from years 2009–2011. NIS is the largest
all–payer inpatient care database in the US and con-
tains discharge level information of 7 to 8 million
hospital stays. This is a 20% stratified clustered sam-
ple from all US hospitals. It is federally sponsored by
Agency for Healthcare Research and Quality [16].
We selected non-pregnant adult patients (≥18 years)
admitted with a diagnosis of heart failure in US hospi-
tals from 2009 to 2011. Patients with heart failure were
selected based on Clinical Classification Software code
108, which represents all patients with parent ICD-9
(International Classification of disease-9) code 428.
CCS codes are supplied by HCUP to facilitate research-
ers into selecting patients with one or few disease con-
ditions grouped together into a clinically meaningful
category (HCUP CCS). We additionally included ICD-
9 codes 402.01, 402.11, 402.91, 404.01, 404.03, 404.11,
404.13, 404.91 and 404.93 to include heart failure
patients not included under CCS code 108.We categor-
ized patients with heart failure into systolic, diastolic,
combined and unspecified based on their coded ICD-9
classification. Analyses were based on 3 different groups
of potassium levels: hypokalemia, normokalemia
(defined as not coded for either hypokalemia or hyper-
kalemia) and hyperkalemia. The ICD-9 codes 267.7 and
276.8 were used to classify hyperkalemia and hypokale-
mia respectively. ICD-9 coding does not specify any
particular potassium levels for these diagnoses.
Patients coded for both hyperkalemia and hypokalemia
were excluded from further analysis. The HCUP-NIS
database also contains data for baseline characteristics
such as age, gender, race, expected primary payer, loca-
tion of hospital and mean household income for
patient’s ZIP code (HCUP-US NIS). The primary out-
come for this study group was in-hospital mortality.
3. Statistical analysis
STATA version 13.0 (College Station, TX) was used for
analysis of this survey sample data. Categorical data
were expressed as proportion or percentage with Chi-
square testing used to compare proportions.
Continuous variables were reported as means with
standard errors. Mortality associations between potas-
sium categories were initially compared by univariate
analysis, then were also included in multivariable logis-
tic regression analyses. Multivariable analyses were
controlled for age, sex, race, smoking, obesity, dyslipi-
demia, diabetes, hypertension, chronic kidney disease
and Charlson comorbidity index (a predictor of 10-year
mortality for patients with multiple comorbidities).
Two tailed p-value of p < 0.05 was assumed to have
statistical significance.
4. Results
The total number of discharge records in the NIS
database (sample) from 2009 to 2011 was 23,634,793.
The weighted count in the universe of the database
(US population) was N = 117,033,987. Details of the
selection process is depicted in Figure 1. Our final
study population was based on 549,044 inpatient hos-
pital discharge records.
The baseline characteristics of HF patients are pre-
sented in Table 1. Hypokalemic heart failure patients
were slightly younger (72.3 vs. 73.6 years, p < 0.001), less
likely to be Caucasian (61.5 vs. 67.3, p < 0.001), more
likely to be admitted to an urban hospital (86.8 vs.
83.2%, p < 0.001), and were more likely to have obesity,
hypertension and diabetes when compared to normo-
kalemic heart failure patients. Chronic renal failure was
much more likely to be present in hypokalemic patients
(69.1% vs 38.8%, p < 0.001). Hyperkalemic heart failure
patients were slightly younger (73.2 vs. 73.6 years,
p < 0.001), slightly more likely to be Caucasian (68.4%
vs. 67.3%), and more likely to have comorbidities of
obesity, smoking and hypertension but less likely to
have chronic kidney disease (36.6% vs. 38.9%,
p < 0.001) as compared to those normokalemic heart
failure patients. We found that higher number of
heart failure inpatients, regardless of potassium
levels, were of lower income than of higher income.
Univariate analysis comparing potassium diag-
nosis and inpatient death showed a lower odds of
inpatient mortality among HF patients coded for
a diagnosis of hyperkalemia as compared to nor-
mokalemia (OR = 0.73, 95% CI: 0.69–0.78) and
a higher odds of mortality among those coded for
a diagnosis of hypokalemia as compared to normo-
kalemia (OR = 2.27, 95% CI: 2.15–2.40). (Table 2)
The reported length of stay was significantly
increased in patients with codes for hypokalemia
and was decreased for hyperkalemia. Patients with
heart failure without a potassium diagnosis code, as
compared to hyperkalemia and hypokalemia, stayed
in the hospital for a mean of 4.55, 5.36 and
5.93 days respectively. Multivariable analysis using
inpatient death as the dependent variable and con-
trolling for age, sex, race, smoking, obesity, dyslipi-
demia, diabetes, hypertension, chronic kidney
disease and Charlson comorbidity index showed
similar significant results as with univariate analy-
sis, with a lower odds of death in those with hyper-
kalemia (OR: 0.77, 95% CI: 0.72–0.83) as compared
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to those without a potassium diagnosis. Similarly,
hypokalemia was associated with a higher odds of
death in multivariate analysis when above factors
were controlled than those without a potassium
diagnosis. (OR: 2.37, 95% CI: 2.24–2.52). (Table 2)
The rate of inpatient mortality of patients with
heart failure without a diagnosis of abnormal potas-
sium, with hyperkalemia and with hypokalemia were
2.85, 2.11 and 6.24 percent respectively (Table 3).
Inpatient mortality among different subcategories of
HF, namely systolic heart failure, diastolic heart
failure and combined systolic and diastolic heart fail-
ure followed similar trends as the composite HF
group (Table 3). Multivariable analysis of mortality
in subtypes of HF and possible etiologies of HF (acute
coronary syndrome, ischemic heart disease, valvular
heart disease, cardiomyopathy, atrial fibrillation) are
presented in Supplementary Table 1. The subtypes
and etiologies follow the same pattern of mortality
among different serum potassium categories as was
seen with HF and its subtypes. All associations were
statistically significant except for hyperkalemic
Figure 1. Selection process for the discharge records used in final analysis.
Table 1. Baseline characteristics of HF patients with different categories of potassium levels.
Baseline characteristics HF with normokalemia HF with hyperkalemia HF with hypokalemia p-value
Age 73.67 (SE:0.15) 73.21 (SE:0.18) 72.39 (SE:0.18) <0.0001
Female 51.13 55.39 52.40 <0.0001
Race
Caucasian 67.37 68.45 61.58 <0.0001
Black 20.40 21.78 22.02
Hispanic 7.61 5.81 10.77
Asian or Pacific Islander 1.65 1.43 2.44
Native American 0.58 0.56 0.56
Expected primary payer
Medicare 76.02 74.69 78.20 <0.0001
Medicaid 7.78 7.63 8.83
Primary insurance 11.16 12.03 9.45
Self-pay 3.11 3.83 2.12
No charge 0.29 0.34 0.22
Location of hospital
Rural 16.73 16.90 13.12 <0.0001
Urban 83.27 83.10 86.88
Mean household income for patient’s Zip code
0–25th percentile 33.24 32.87 33.00 <0.0001
26th–50th percentile 26.42 26.04 24.99
51st–75th percentile 22.71 23.38 23.50
76th–100th percentile 17.64 17.70 18.51
Mean Charlson comorbidity index 3.16 3.06 3.99 <0.0001
Risk factors
Obesity 14.20 14.96 15.10 <0.0001
Smoking 21.31 22.41 21.10 0.0001
Hypertension 75.69 77.32 81.15 <0.0001
Dyslipidemia 39.36 39.68 37.90 0.0006
Diabetes mellitus 43.62 39.35 53.36 <0.0001
Chronic kidney disease 38.86 36.64 69.12 <0.0001
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patients with combined systolic and diastolic, valvular
heart disease, hypertensive heart disease and cardio-
myopathy in comparison to normokalemia.
5. Discussion
In this US database study, we found increased inpa-
tient mortality in HF patients diagnosed with hypo-
kalemia when compared to those without abnormal
potassium diagnosis, which is in line with prior out-
patient studies [2–5,12]. Our study found a higher
overall calculated risk of mortality in comparison to
other studies except Hoss et al., where their odds
ratio was comparable to ours [2–5,12]. Our findings
of increased mortality risk were similar regardless of
the subtype or etiology of HF (OR: 2.16–5.94).
The risk for developing hyperkalemia increases with
advancing age, male gender, renal failure and diabetes,
all of which are themselves independently associated
with chronic kidney disease [13,15,17]. Paradoxically,
our cohort identified significantly more CKD in the
hypokalemic HF patients than the normokalemic or
hyperkalemic groups. It is possible that hypokalemia is
a marker for patients who have more decompensated
heart failure and/or higher diuretic doses, a theory pos-
tulated by Bowling et al. to explain the higher rates of
death and rehospitalization in their cohort of HF
patients with hypokalemia [4]. We found that hyperka-
lemia was associated with an overall small but decreased
odds of mortality amongHF patients without abnormal
potassium. Although some heart failure etiologies and
subtypes did not demonstrate a significant association
between hyperkalemia and decreased mortality, none
showed a significant increase in mortality. This finding
is in line with previous studies which showed either no
difference of a decrease in mortality associated with
hyperkalemia [5,18]. This finding is particularly impor-
tant because of the increase in inpatient mortality seen
following the publication of the RALES trial, in which
hyperkalemia related hospitalizations and mortality
both increased [14], a finding that made physicians
more concerned about the use of evidence based med-
icines that may be associated with hyperkalemia alone
or in combination.
6. Limitations
The database that we utilized uses ICD-9 codes to
categorize potassium disorders. No ICD-9 definitions
specify what levels of potassium constitute hypo- or
hyperkalemia. It was not possible to know whether
potassium abnormalities were one-time or sustained.
Potassium abnormalities that occurred only once
should be less likely to result in mortality.
Furthermore, it is possible that hypokalemia may be
a confounding variable for patients who needed more
aggressive diuresis due tomore significant volume over-
load; if this is the case, hypokalemiamay be amarker for
disease severity but not an independent risk factor on its
own. We were not able to subcategorize high serum
potassium into multiple groups as was done by Hoss
et al. and Ahmed et al. and calculate mortality risk in
high-normal serum potassium (serumK 5.0–5.5 mEq/l)
due to the aforementioned limitations in the ICD-9
diagnoses [5,18]. This limitation would be present
using ICD-10 coding as well. It is possible that hospitals
with greater resources may have had coding personnel,
allowing them to identify hyperkalemia in their heart
failure patients more often, which would raise the ques-
tion of whether other unmeasured confounders such as
patient or hospital resources may explain differences in
Table 2. Univariate and multivariable analyses with logistic regression of mortality, length of stay (LOS) and cost among HF
patients in relation to normokalemia.
Characteristics
Unadjusted Odds Ratio
OR (95% CI), p-value
Adjusted* Odds Ratio
OR (95% CI), p-value
Mortality
Hyperkalemia 0.73 (0.69–0.78), p < 0.001 0.77 (0.72–0.83), p < 0.001
Hypokalemia 2.27 (2.15–2.40), p < 0.001 2.37 (2.24–2.52), p < 0.001
LOS
Hyperkalemia 0.81 (0.74–0.88), p < 0.001 0.88(0.81–0.94), p < 0.001
Hypokalemia 1.37 (1.30–1.45), p < 0.001 1.16 (1.09–1.24), p < 0.001
Cost
Hyperkalemia 1270.81 (1083.19–1458.44), p < 0.001 1428.22 (1229.40–1627.04), p < 0.001
Hypokalemia 3070.33 (2855.78–3284.89), p < 0.001 2511.57 (2307.19–2715.95), p < 0.001
*Adjusted for age, sex, race, smoking, obesity, dyslipidemia, diabetes, hypertension, Charlson comorbidity index.
Table 3. Classification of mortality in HF and based on etiol-











HF 2.85 2.11 6.24 <0.0001
SHF 2.50 1.94 6.58 <0.0001
DHF 2.12 1.79 4.75 <0.0001
SDHF 2.58 2.19 5.42 <0.0001
IHD 2.67 2.21 5.35 <0.0001
VHD 2.87 2.01 7.16 <0.0001
HHD 0.82 0.75 5.75 0.06
CM 2.08 1.40 4.88 <0.0001
AF 3.88 2.72 9.92 <0.0001
(HF: heart failure; SHF: systolic heart failure; DHF: diastolic heart failure;
SDHF: systolic and diastolic heart failure; UHF: unspecified heart failure;
ACS: acute coronary syndrome; IHD: ischemic heart disease; VHD:
valvular heart disease; HHD: hypertensive heart disease; CM: cardio-
myopathy; AF: atrial fibrillation)
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mortality seen in our study. However, those same cod-
ing resources would also have identified hypokalemia,
and the hypokalemic cohort fared significantly worse
than those patients without potassium diagnoses.
Furthermore, surrogate analysis of patient ZIP codes
did not suggest that the cohorts had very different
financial resources. Although ICD −9 does distinguish
between acute and chronic heart failure, we chose to
select all heart failure diagnoses in the first two diag-
nosis positions in order to most broadly capture all
heart failure patients for whom it was believed heart
failure was one of their top two admission diagnoses.
Despite this, it is possible that some of the patients
included in the study may have had chronic but not
acute decompensated failure.
7. Conclusion
Hypokalemia is associated with an increased odds of
mortality among patients with HF, regardless of the
etiology or type of heart failure. Conversely, hyperka-
lemia, is associated with a similar or lower odds of
mortality. Whether our mortality findings translate to
longer-term outpatient settings where significantly
less monitoring is possible is a matter for further
study, but our current work supports the use of
aggressive goal-directed therapy and establishment
of normal potassium levels in the inpatient setting.
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